KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Enterprise Value (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Enterprise Value data on record, last reported at -$819.7 million in Q4 2025.

  • For Q4 2025, Enterprise Value fell 8.43% year-over-year to -$819.7 million; the TTM value through Dec 2025 reached -$819.7 million, down 8.43%, while the annual FY2025 figure was -$819.7 million, 8.43% down from the prior year.
  • Enterprise Value reached -$819.7 million in Q4 2025 per ACAD's latest filing, up from -$847.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$345.9 million in Q3 2023 and bottomed at -$847.0 million in Q3 2025.
  • Average Enterprise Value over 5 years is -$544.9 million, with a median of -$510.8 million recorded in 2021.
  • Peak YoY movement for Enterprise Value: rose 22.81% in 2022, then plummeted 72.26% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$520.7 million in 2021, then increased by 19.95% to -$416.8 million in 2022, then decreased by 5.29% to -$438.9 million in 2023, then crashed by 72.26% to -$756.0 million in 2024, then dropped by 8.43% to -$819.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$819.7 million in Q4 2025, -$847.0 million in Q3 2025, and -$762.0 million in Q2 2025.